Both contained the same phospho-Tau peptide from the C-terminal region of the Tau protein (Tau393-408 [pS396/pS404]), considered a relevant phosphorylated region related to AD pathology and abundantly present on PHF.19, 20, 21, 22 The formulations differed in the structural element used to present the phospho-Tau peptide to the immune system and the selection of adjuvants, key drivers of successful active immunotherapies. The gene discussed is MAPT; the disease is Alzheimer disease.